

Removal of Temporary Benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Acetylcystine 20% Inhalation Solution (DIN 02243098) manufactured by Sandoz Canada Inc., **Acetylcystine 20% Inhalation Solution USP (DIN 02459906)** manufactured by Hikma Pharmaceuticals PLC (Teligent Canada, Inc.) was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross® has confirmed that the shortage for Acetylcystine 20% Inhalation Solution (DIN 02243098) has been resolved.

Acetylcystine 20% Inhalation Solution USP (DIN 02459906) will no longer be considered a temporary benefit for the *ADBL* after **November 30, 2023**. The above grouping was removed from the Critical Supply Product List **October 31, 2023**.

Due to the shortage of Vyvanse 20 mg Capsule (DIN 02347156) manufactured by Takeda Canada, Inc., **Vyvanse 10 mg Capsule (DIN 02439603)** manufactured by Takeda Canada, Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross has confirmed that the shortage for Vyvanse 20 mg Capsule (DIN 02347156) has been resolved.

Vyvanse 10 mg Capsule (DIN 02439603) will no longer be considered a temporary benefit for the *ADBL* after **December 1, 2023**. The above grouping was removed from the Critical Supply Product List **November 1, 2023**.

Temporary benefit added to the *ADBL*

Due to the unavailability of Valcyte 50 mg/mL Oral Suspension (DIN 02306085) manufactured by Cheplapharm Arzneimittel GmbH Germany, **Auro-Valganciclovir 50 mg/mL Oral Suspension (DIN 02535483)** manufactured by Auro Pharma Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **November 6, 2023**.

As of **November 6, 2023**, all claims for **Auro-Valganciclovir 50 mg/mL Oral Suspension (DIN 02535483)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.php

continued next page

continued from previous page

Product supply shortages addressed for ADBL

Alberta Blue Cross has confirmed that the shortage for Auro-Ziprasidone 20 mg Capsule (DIN 02449544) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **December 6, 2023**. The following grouping was removed from the Critical Supply Product List **November 6, 2023**.

ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE

20 MG CAPSULE

00002449544	AURO-ZIPRASIDONE	AUR	\$ 1.3784
00002298597	ZELDOX	UJC	\$ 2.0182

Alberta Blue Cross has confirmed that the shortages for Auro-Trandolapril 0.5 mg Capsule (DIN 02471868) and pms-Trandolapril 0.5 mg Capsule (DIN 02357755) have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **December 6, 2023**. The following grouping was removed from the Critical Supply Product List **November 6, 2023**.

TRANDOLAPRIL

0.5 MG CAPSULE

00002471868	AURO-TRANDOLAPRIL	AUR	\$ 0.0698
00002357755	PMS-TRANDOLAPRIL	PMS	\$ 0.0698
00002325721	SANDOZ TRANDOLAPRIL	SDZ	\$ 0.0698
00002231457	MAVIK	BGP	\$ 0.2790

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

